In a child with X-linked severe combined immunodeficiency who develops T-lymphocyte leukemia after gene therapy, what viral process likely caused the leukemia?

• A. Deactivation of the p53 tumor suppressor gene
• B. Generation of the Philadelphia (Ph1) chromosome
• C. Integration adjacent to an oncogene
• D. Reverse transcription of PTEN

Answer: (C)

In the scenario where a child with X-linked severe combined immunodeficiency (X-SCID) develops T-lymphocyte leukemia following gene therapy, the most likely viral process that contributed to the leukemia involves the integration of the therapeutic viral vector adjacent to an oncogene.

Gene therapy for X-SCID often utilizes retroviral vectors to deliver a functional copy of the IL2RG gene. These vectors integrate into the host genome, and if the integration occurs near an oncogene, it can activate that oncogene. This can lead to uncontrolled cell proliferation and eventually leukemia, particularly in hematopoietic cells like T-lymphocytes, which are already compromised in these patients.

In this context, the integration of the viral vector adjacent to an oncogene disrupts normal regulation and can cause malignant transformation. This mechanism is supported by instances seen in gene therapies utilizing retroviral vectors, where insertional mutagenesis leads to the activation of nearby oncogenes, resulting in cancer development. Therefore, the integration adjacent to an oncogene is a significant concern in retroviral gene therapy, leading to the potential risk of oncogenesis in treated individuals.